Nowe potencjalne klasy leków w nadciśnieniu

Michel Aziz i wsp. Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension. 2019;74:1075–1083 (dostępny pełen tekst ang.)

These include dual angiotensin II receptor-neprilysin inhibitors, soluble guanylate cyclase stimulators, nonsteroidal dihydropyridine-based mineralocorticoid receptor antagonists, as well as sodium-glucose cotransporter 2 inhibitors. However, centrally acting aminopeptidase A inhibitors and endothelin receptor antagonists have a dedicated program of development for hypertension …

Hypertension, listopad 2019

Dodaj komentarz